<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927949</url>
  </required_header>
  <id_info>
    <org_study_id>20-126</org_study_id>
    <nct_id>NCT04927949</nct_id>
  </id_info>
  <brief_title>Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not</brief_title>
  <acronym>ERMIT</acronym>
  <official_title>Evaluation of Myocardial Reperfusion and Residual Thrombotic Burden After Primary PCI for STEMI in Patients With High on Ticagrelor Platelet Reactivity Treated by IV Cangrelor Versus Ticagrelor Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terumo Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic&#xD;
      burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary&#xD;
      PCI patients with high on ticagrelor platelet reactivity compared to standard of care with&#xD;
      ticagrelor alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the use of potent P2Y12 inhibitor such as ticagrelor, half of the patients presented&#xD;
      high platelet reactivity (HPR) at the time of primary percutaneous coronary intervention&#xD;
      (PCI) for ST-elevation myocardial infarction (STEMI). HPR has been associated with impaired&#xD;
      myocardial reperfusion. Myocardial reperfusion, assessed using myocardial blush grade, is a&#xD;
      strong prognostic factor associated with infarct size and mortality. Antiplatelet therapy&#xD;
      intensification using a potent and immediate P2Y12 inhibitor such as Cangrelor according a&#xD;
      point-of-care platelet function test has not been studied in the acute phase of STEMI.&#xD;
&#xD;
      This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic&#xD;
      burden of adding Cangrelor to ticagrelor in primary PCI patients with high on ticagrelor&#xD;
      platelet reactivity compared to standard of care with ticagrelor alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade of myocardial blush</measure>
    <time_frame>during procedure</time_frame>
    <description>myocardial blush grade from 0 to 3 (normal)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of residual thrombus burden</measure>
    <time_frame>during procedure</time_frame>
    <description>intrastent residual thrombus burden assessed by optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of platelet reactivity</measure>
    <time_frame>during procedure</time_frame>
    <description>Platelet reactivity using VerifyNow after PCI for patients with basal platelet reaction unit&gt;208</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>troponin</measure>
    <time_frame>day 1</time_frame>
    <description>peak value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infarct size and no reflow on MRI</measure>
    <time_frame>during hospitalization assessed up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical outcomes</measure>
    <time_frame>during hospitalization assessed up to 7 days</time_frame>
    <description>death, new myocardial infarction, stent thrombosis, new revascularization, stroke, major bleeding</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>patients without HPR</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>standard primary PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with HPR randomized to cangrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cangrelor perfusion started before PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with HPR randomized to standard of care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard primary PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cangrelor perfusion during PCI</intervention_name>
    <description>Cangrelor perfusion (started before PCI) with intravenous bolus of 30 microgram/kg, followed by a perfusion of 4 microgram/kg/min during 2 hours or until the end of the PCI if longer</description>
    <arm_group_label>patients with HPR randomized to cangrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard PCI</intervention_name>
    <description>primary PCI without cangrelor</description>
    <arm_group_label>patients with HPR randomized to standard of care</arm_group_label>
    <arm_group_label>patients without HPR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient admitted for STEMI within 24 hours from symptom onset&#xD;
&#xD;
          -  pretreated with ticagrelor, aspirin and enoxaparin (according local protocol)&#xD;
&#xD;
          -  successfully treated by primary PCI of a native coronary culprit lesion&#xD;
&#xD;
          -  anatomy accessible to optical coherence tomography (OCT or OFDI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cardiogenic shock&#xD;
&#xD;
          -  stent restenosis or thrombosis&#xD;
&#xD;
          -  use of glycoprotein IIb/IIIa inhibitors before or during PCI&#xD;
&#xD;
          -  known coagulation disease&#xD;
&#xD;
          -  high bleeding risk (thrombocytopenia &lt;100,000/dL, surgery &lt;30 days, active bleeding)&#xD;
&#xD;
          -  uncontrolled arterial hypertension (&gt;180/110 mmHg)&#xD;
&#xD;
          -  history of stroke (ischemic or hemorrhagic) or transient ischemic attack&#xD;
&#xD;
          -  known severe renal insufficiency (eGFR &lt;30 ml/min)&#xD;
&#xD;
          -  oral anticoagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>vincent ROULE, MD PhD</last_name>
    <phone>+33231063048</phone>
    <email>roule-v@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CAEN University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>vincent ROULE, MD PhD</last_name>
      <phone>+33231063048</phone>
      <email>roule-v@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Farzin BEYGUI, MD PhD</last_name>
      <phone>+33231063350</phone>
      <email>beygui-f@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>adrien LEMAITRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>mathieu BIGNON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>rémi SABATIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>katrien BLANCHART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>clément BRIET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>idir REBOUH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cangrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

